Tay-Sachs and rare disease registries – the Health Heroes podcastEpisode four of Kantar Health’s Health Heroes podcast tackles pharma’s rare disease challenges, the role of patient registries Share XTay-Sachs and rare disease registries – the Health Heroes podcasthttps://pharmaphorum.com/podcast/rare-disease-registries-kantar-health/
Touchpoint optimisation: time for multichannel marketing to reconnect the brand story and the customer As the digital era of communication continues to expand and flourish, the way life sciences companies interact Share XTouchpoint optimisation: time for multichannel marketing to reconnect the brand story and the customerhttps://pharmaphorum.com/debates-insight-sales-marketing/touchpoint-optimisation-time-multichannel-marketing-reconnect-brand-story-customer/
Nokia, Kantar collaborate for diabetes database projectDeal looks to measure impact of ‘Lifestyle Therapy’ on diabetes treatment. Share XNokia, Kantar collaborate for diabetes database projecthttps://pharmaphorum.com/news/nokia-kantar-diabetes-database/
Ibrance approval cemented as competition comes into viewIn February 2015, Pfizer’s Ibrance (palbociclib) was granted accelerated approval by the FDA for treatment of newly diagnosed Share XIbrance approval cemented as competition comes into viewhttps://pharmaphorum.com/partner-content-oncology/ibrance-approval-cemented-competition-comes-view/
Does NEMO bring us a step closer in the fight against melanoma?Options for treatment in metastatic melanoma have increased significantly in terms of efficacy and reduction of mortality in Share XDoes NEMO bring us a step closer in the fight against melanoma?https://pharmaphorum.com/partner-content-oncology/nemo-bring-us-step-closer-fight-melanoma/
Further Darzalex results extend hope for PFS in MyelomaEarlier this year (March), Johnson & Johnson announced that the randomized Phase III CASTOR trial (NCT02136134) achieved its Share XFurther Darzalex results extend hope for PFS in Myelomahttps://pharmaphorum.com/partner-content-oncology/further-darzalex-results-extend-hope-for-pfs-in-myeloma/
Positive PIII results for VYXEOS revealed at ASCOBuilding on the announcement made in March of this year, Celator Pharmaceuticals has today (June 4th) presented the Share XPositive PIII results for VYXEOS revealed at ASCOhttps://pharmaphorum.com/partner-content-oncology/positive-piii-results-for-vyxeos-revealed-at-asco/